Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Idaho for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Idaho only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Idaho (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Stephanie Hodson (NPI 1265478374)

Field	Value
Entity Type	Individual
Organization	Stephanie Hodson
Address	2855 E Magic View Dr
City	Meridian
State	ID
ZIP	83642
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 20, 2006

Payer Source	Total Paid
Medicare	$477.8K
Medicaid	$0

Key Findings

This provider’s Medicare activity is the only payer volume on file: total Medicare revenue is $477.8K and there is no Medicaid billing on file, so operations appear effectively single‑payer with Medicare as the primary revenue source. That concentration will matter for network negotiations and risk attribution because there is no Medicaid offset or diversification evident in the claims data.

Revenue is heavily concentrated in a small number of codes: the top three Medicare codes (J0897, Q5122, 99214) account for 62.9% of total Medicare revenue. Individually those codes contribute 38.1% (J0897), 16.0% (Q5122), and 8.8% (99214), indicating the practice derives the majority of its Medicare dollars from a few high‑use biologic injections and office E/M visits.

The code mix (high volumes of J0897 and Q5122 plus chemotherapy and E/M codes) signals an oncology practice focused on in‑office biologic/supportive injections and outpatient management. Supporting details include 96413 (chemotherapy) with 297 claims and $26.4K revenue (5.5% of Medicare revenue) and M0010 (EOM monthly enhanced oncology services) with 181 claims and $13K revenue (2.7%), which together point to a combined infusion/care management operation rather than a pure procedural or inpatient practice.

For its top injectable, J0897 (denosumab), the provider reports 10.1K claims and $181.4K revenue (38.1% of Medicare revenue) and ranks #1129 of 10057 providers nationally (89th percentile; typical, unremarkable volume for this code). This places the provider above the median national peer for denosumab administration but still within the dataset’s characterization of a typical, unremarkable volume profile rather than as a national outlier or dominant provider.

The provider’s use of Q5122 (pegfilgrastim‑apgf biosimilar) is comparatively concentrated: 840 claims, $76.4K revenue (16.0% of Medicare revenue), ranking #22 of 239 providers nationally (91th percentile; typical, unremarkable volume for this code). That rank indicates a relatively high standing among peers who bill this biosimilar, reinforcing a focus on supportive oncology care products within the practice mix.

E/M and chemotherapy activity appear above average relative to national peers but still described as typical: 99214 (476 claims, $41.9K revenue, 8.8% of Medicare revenue) ranks #52974 of 479517 providers (89th percentile; typical, unremarkable volume) and 96413 (297 claims, $26.4K revenue) ranks #1871 of 7514 providers (75th percentile; typical, unremarkable volume). These positions suggest steady outpatient oncology follow‑up and treatment throughput rather than anomalous billing patterns.

There is one clear statistical signal of higher than typical volume: 96402 (subcutaneous/intramuscular hormonal anti‑neoplastic administration) has 130 claims and $2.6K revenue (0.5% of Medicare revenue) and ranks #343 of 4765 providers nationally (93th percentile; notably above typical national volume). That elevated rank for 96402 suggests a specific procedural niche (subcutaneous hormonal anti‑neoplastic therapy) where this provider is materially more active than most peers.

Operationally, the dataset shows very high claim counts for some J‑codes but low average paid amounts per claim, for example J0897 (10.1K claims; $18 avg paid/claim) and J9171 (6.8K claims; $1 avg paid/claim with $6.8K revenue). This pattern implies that overall revenue is driven by large administration volumes of lower‑unit‑priced drugs and biologics rather than by a small number of very high‑paid per‑claim services, which has implications for inventory, billing oversight, and supplier contracting.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

40 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0897	Injection, denosumab, 1 mg	10,080	$20	$181.4K
Q5122	Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg	840	$90	$76.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	480	$90	$41.9K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	220	$130	$28.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	300	$90	$26.4K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	370	$60	$21.2K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	140	$140	$19.4K
M0010	Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services	180	$70	$13K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	60	$150	$9.2K
J9171	Injection, docetaxel, 1 mg	6,780	$1	$6.8K

Showing 1–10 of 40

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 40 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Idaho Distribution

Stephanie Hodson — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Idaho

Full comparison — all codes billed, vs. state median

40 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
Q5122	1	10	840	$90	$76.4K
J0897	3	30	2,580	$20	$76.2K
96413	7	20	250	$90	$26K
J9217	5	10	130	$130	$19K
99214	158	2,690	90	$70	$10.4K
M0010	1	10	120	$70	$8.7K
96365	12	20	80	$40	$7.4K
96417	3	10	70	$50	$6.7K
99215	46	810	40	$100	$6.5K
J0185	1	10	4,750	$1	$6.5K

Showing 1–10 of 40

Related Providers

Other providers that share a Tax Identification Number (TIN) with Stephanie Hodson, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Ali Torab Parhiz	ID	Ophthalmology Physician	$4.3M	$7.8K
Arvind Chaudhry	WA	Hematology & Oncology Physician	$2.9M	$0
Mirela Andrei	WA	Medical Oncology Physician	$1M	$0
Karie-lynn Kelly	WA	Radiation Oncology Physician	$1M	$0
Myles Mitsunaga	CA	Diagnostic Radiology Physician	$510.8K	$113.9K
Norman Willis	ID	Radiation Oncology Physician	$573.4K	$0
Hugh Mcswain	CA	Neuroradiology Physician	$235.3K	$292.6K
Ravi Rajpoot	MD	Diagnostic Radiology Physician	$123K	$316.3K
St Alphonsus Professional Medical Services LLC	ID	Anesthesiology Physician	$0	$407.2K
Sean Creeden	IL	Neuroradiology Physician	$98.7K	$252.1K

Nearby Providers

Other providers in the same ZIP code as Stephanie Hodson, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Norco, Inc.	ID	Durable Medical Equipment & Medical Supplies	$0	$41M
Joint School District No. 2	ID	Local Education Agency (LEA)	$0	$34.2M
Chatterbox Speech & Language Center	ID	Speech-Language Pathologist	$0	$10.6M
St. Fillan's, LLC	ID	In Home Supportive Care Agency	$0	$10.5M
Southern Idaho Health Partners LLC	ID	General Practice Physician	$0	$9.2M
Gem State Developmental Center LLC	ID	Developmentally Disabled Services Day Training Agency	$0	$9.1M
Addus Healthcare, Inc.	ID	In Home Supportive Care Agency	$0	$6.1M
Northwest Neurobehavioral Health, LLC	ID	Clinical Social Worker	$0	$5.2M
Idaho Pediatric Therapy Clinic PLLC	ID	Physical Therapist	$0	$3.1M
Cpapnow Inc	ID	Durable Medical Equipment & Medical Supplies	$0	$3.1M

Stephanie Hodson — Billing Profile & Reimbursement Data

Sign up for Stephanie Hodson — Billing Profile & Reimbursement Data policy alerts

Stephanie Hodson — Billing Profile & Reimbursement Data

Sign up for Stephanie Hodson — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References